◇Korea AstraZeneca Posey approved additional indications for treatment of chronic heart failure
AstraZeneca Korea (CEO Sang-pyo Kim)’s SGLT-2 inhibitor type 2 diabetes drug Posiga (ingredient name: Dapagliflozin) was approved by the Ministry of Food and Drug Safety to add an indication for treatment of chronic heart failure on December 22nd.
According to the additional indications, Posiga can be used for the treatment of chronic heart failure patients 18 years of age or older with reduced left ventricular contractile function.
This makes Fociga the first SGLT-2 inhibitor used to treat heart failure with or without diabetes.
Heart failure is a disease that cannot supply the amount of blood necessary for metabolism in the body due to decreased heart function.The goal of heart failure treatment is ▲improving the clinical condition of heart failure patients, ▲improving the range of functions and quality of life of patients, ▲preventing hospitalization and mortality It is a reduction. As drugs for improving the survival rate, renin-angiotensin blockers and beta blockers are being used.
The DAPA-HF study was the basis for the addition of the indication for the treatment of heart failure in Posey. DAPA-HF has decreased left ventricular systolic function regardless of type 2 diabetes (left ventricular ejection rate [LVEF] 40% or less) A total of 4744 patients with chronic heart failure (NYHA functional class II to IV) were studied, and about 55% of the total were patients without type 2 diabetes.
In addition, more than 94% of patients were taking renin-angiotensin blockers, and more than 96% of patients were taking beta blockers.
According to the results of the DAPA-HF study, Posiga reduced the risk of exacerbation of heart failure and death from cardiovascular disease, the primary endpoint, by 26% compared to placebo.
In addition, the risk of death from all causes and cardiovascular death were both reduced by 17% and 18% compared to placebo, respectively.
In particular, in the group of patients without type 2 diabetes, the risk of deteriorating heart failure and death from cardiovascular disease was lowered by 27% compared to placebo, confirming that it is effective for heart failure regardless of diabetes.
The safety profile of Fociga confirmed in the DAPA-HF study was consistent with the previous studies.
Il Shim, Managing Director of CVRM Division of AstraZeneca Korea, said, “We are pleased to be able to provide a new treatment option for Posiga to improve the survival rate of heart failure patients.” “It will be an important starting point for presenting a milestone for SGLT-2 inhibitors that are expanding as treatments for heart failure.”
◇ Sanofi completes’A special Christmas at Green Santa Imagination School’
Sanofi-Aventis Korea (representative background) announced that it successfully completed the ‘2020 Green Santa Imagination School’s Special Christmas’ online program with Beautiful Store, Daum Foundation, and Youth Voice.
Abstract Santa Sangsang School is an integrated psychological support education program that helps children and their families with physical diseases such as chronic and rare and intractable diseases, cancer, etc., relieve stress from the treatment process and daily life, and to grow emotionally and healthy.
‘2020 Green Santa Imagination School’s Special Christmas’ is the second Green Santa Imagination School program held by Sanofi this year in the ‘2020 Green Santa Online Imagination School’ which was completed in August.
Sanofi has been holding Green Santa Imagination School once a year during the summer vacation for children. However, this year, in response to the enthusiastic support of the participants of the ‘2020 Green Santa Imagination School’ and the request of the child’s family who missed the opportunity to participate, the ‘2020 Green Santa Imagination School’s Special Christmas’ online program will be additionally operated.
The application for this’Special Christmas at Green Santa Imagination School’ program was closed early, with 114 applicants, almost twice the number of participants, applying for about 3 days after recruiting.
The program was run three times on December 16th, 19th and December 22nd with 100 participants from all over the country, and consisted of three programs for children and their siblings.
In the 1st round, I looked back at my year with the concept of a Christmas tree ▲Dreamcatcher class to make a wish was held, and in the 2nd and 3rd rounds, Rudolph paper dolls that family can play with ▲Pinata making and gift boxes for friends ▲ We conducted a class on making a surprise gift box.
Although it is an online class, a class kit was delivered to the child’s family so that children with longer stay indoors can enjoy the class with their families.
Participation in the program, including kit items required for each class, was completely free, and participants who participated in the 3rd program and delivered the results to the management secretariat will receive a surprise gift prepared by Green Santa.
Background-eun Sanofi said, “We are grateful for the passion and love that children’s families send to Green Santa Sangsang School, such as the early closing of applications for special Christmas at Green Santa Sangsang School. He said, “As a healthy life partner, Sanofi will continue to care for the entire life of the patient and his/her family, and contribute to improving social awareness of diseases such as chronic, rare and intractable diseases, and cancer.” .
Sanofi-Aventis Korea’s representative social responsibility program,’Choroxanta’, celebrates its 16th anniversary this year, so that children, adolescents, and young people suffering from chronic and rare intractable diseases and cancer can grow emotionally and healthier in the treatment process and daily life. It was designed to apply.
Sanofi aims to resolve misunderstandings and prejudices on diseases such as chronic and rare intractable diseases and cancer through the Green Santa program and improve social awareness in the long term.
Green Santa is a’Imagination School’ for elementary school students, a’Imagination Workshop’ for middle and high school students, a’Imagination Playground’ with citizens, and social activities for young patients in their twenties operated as a pilot in 2019. It consists of the campaign’Imagination Starter’.
Copyright © Medical News Unauthorized reproduction and redistribution prohibited